Back to News
Market Impact: 0.25
FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients
Source: reuters.com
Healthcare & BiotechRegulation & LegislationTechnology & InnovationCompany Fundamentals

The FDA authorized Abbott Laboratories’ new glucose monitor, the first device to continuously track both ketone levels and blood sugar. This is a regulatory milestone that supports product differentiation in diabetes management, which should be viewed as modestly positive for Abbott’s prospects.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ABT0.65
More News
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- Penske Automotive agrees to be taken private by Penske, Mitsui
- Supermicro promised a new CFO in December 2024. A $2.5 billion smuggling case and a co-founder’s arrest later, it has one
- Blackstone President Jon Gray Bets Big on AI Boom
- What's behind the sell-off in AI neocloud stocks like CoreWeave and Nebius
- Eight states sue OpenAI saying ChatGPT hurt kids and lied to adults
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Private Equity Due Diligence: A Buyer Workflow
- Weekly Update: In-App Tutorials, Futures Data, and Watchlist Enhancements